Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502.

Grochowicki, M; Khalfallah, Y.; Vighetto, Alain; Berquet, S; Sassolas, G.

doi:10.1136/bjo.77.12.785

Search citation statements

Order By: Relevance

Paper Sections

Select...

Methods1

Diet and Lifestyle1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

2017

Publication Types

Select...

Article2

Book1

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For all patients who underwent surgery, tissue diagnosis was the primary method for making the diagnosis. Patients had VF testing (Humphrey or Goldmann), 4 , 5 including at the time of first evaluation, as part of our clinical protocol.…”

Section: Methodsmentioning

confidence: 99%

Radiological Growth Patterns of Prolactinomas and Nonfunctioning Adenomas

Imran

Shankar

Hebb

et al. 2017

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Radiological Growth Patterns of Prolactinomas and Nonfunctioning Adenomas

Imran

Shankar

Hebb

et al. 2017

Can. J. Neurol. Sci.

View full text Add to dashboard Cite

show abstract

“…Other dopamine agonists such as pergolide or quinagolide (CV 205-502) [28] have also been tried in patients with prolactinomas. This review will discuss bromocriptine and cabergoline, which are the two most commonly used in this setting.…”

Section: Diet and Lifestylementioning

confidence: 99%

Pituitary adenomas

Liu

2002

Curr Treat Options Neurol

View full text Add to dashboard Cite

Treatment of pituitary adenomas can be pharmacologic or surgical. First- line treatment of prolactinomas is usually medical, using either bromocriptine or cabergoline. Other symptomatic pituitary adenomas typically should be treated with transsphenoidal surgery. Radiation therapy can be adjunctive for residual or recurrent tumor. The prognosis for endocrinologic and visual improvement is usually good.

show abstract